AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA

AXQ Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,335 shares of the company’s stock, valued at approximately $285,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTLA. Voya Investment Management LLC increased its stake in shares of Intellia Therapeutics by 621.5% in the first quarter. Voya Investment Management LLC now owns 208,009 shares of the company’s stock worth $1,479,000 after purchasing an additional 179,180 shares in the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Intellia Therapeutics by 108.0% in the second quarter. D.A. Davidson & CO. now owns 54,120 shares of the company’s stock worth $508,000 after buying an additional 28,100 shares in the last quarter. Cyndeo Wealth Partners LLC bought a new position in shares of Intellia Therapeutics during the second quarter worth $101,000. Ballentine Partners LLC bought a new position in shares of Intellia Therapeutics during the second quarter worth $161,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Intellia Therapeutics during the second quarter valued at $166,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.10% of the stock is owned by company insiders.

Intellia Therapeutics Trading Up 1.7%

Shares of NTLA opened at $8.35 on Tuesday. The company’s fifty day simple moving average is $16.57 and its 200-day simple moving average is $12.57. The company has a market cap of $967.18 million, a P/E ratio of -1.96 and a beta of 2.45. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The company had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the prior year, the firm posted ($1.34) EPS. The firm’s revenue was up 51.6% compared to the same quarter last year. Analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTLA has been the topic of several research analyst reports. Bank of America decreased their price target on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. William Blair lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, October 27th. Guggenheim downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Tudor Pickering set a $14.50 price objective on Intellia Therapeutics in a report on Tuesday, October 28th. Finally, Jones Trading downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $18.43.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.